Prasugrel, called by Effient™ and Efient® in the US and Europe, is an oral anti-platelet agent discovered in collaboration Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) and UBE. and codeveloped by Daiichi Sankyo and the US firm Eli Lilly and Company, for which UBE manufactures and supplies the active harmaceutical ingredient (API). It has been approved in Europe, the US and other countries, and is now available for sale in those markets.
Prasugrel reduces the incidence of myocardial infarction and stroke due to the inhibition of activation and aggregation of plateletsinside and on the walls of blood vessels. Clinical trials of prasugrel for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) was conducted, and it demonstrated superior efficacy than the control drug. Clinical trials for ACS, stroke are also underway in Japan.